Pertussis control: Time for something new?

Trends in Microbiology

Volumn 20, Issue 5, 2012, Pages 211-213

  Clark, Thomas A ^a   Messonnier, Nancy E ^a   Hadler, Stephen C ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Epidemiology; Pertussis; Vaccines

Indexed keywords

ACELLULAR VACCINE; ADJUVANT; BACTERIUM LIPOPOLYSACCHARIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; VACCINE; WHOLE CELL VACCINE;

DRUG APPROVAL; DRUG SAFETY; HUMAN; IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; NOTE; PERTUSSIS; PRIORITY JOURNAL; UNITED STATES;

BORDETELLA PERTUSSIS; COMMUNICABLE DISEASE CONTROL; HUMANS; PERTUSSIS VACCINE; VACCINATION; WHOOPING COUGH;

EID: 84860546811     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.03.003     Document Type: Note

References (15)

1. Cherry J.D. The present and future control of pertussis. Clin. Infect. Dis. 2010, 51:656-662.
2. Spokes P.J., et al. Review of the 2008-2009 pertussis epidemic in NSW: notifications and hospitalisations. N.S.W. Public Health Bull. 2010, 21:167-173.
3. Skoff T.H., et al. Early impact of the US Tdap vaccination program on pertussis trends. Arch. Pediatr. Adolesc. Med. 2012, 166:344-349.
4. Greenberg D.P., et al. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr. Infect. Dis. 2009, 28:521-528.
5. Quinn H.E., McIntyre P.B. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull. World Health Organ. 2011, 89:666-674.
6. Centers for Disease Control and Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP). MMWR 2011, 60:1424-1426.
7. Booy R., et al. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine 2011, 29:45-50.
8. Halperin S.A., et al. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine 2011, 29:8459-8465.
9. Ward J.I., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. 2005, 13:1555-1563.
10. Rank C., et al. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr. Infect. Dis. J. 2009, 28:152-153.
11. Wei S.C., et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin. Infect. Dis. 2010, 51:315-321.
12. Bisgard K.M., et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005, 116:e285-e294.
13. Mills K.H.G. Immunity to Bordetella pertussis. Microbes Infect. 2001, 3:655-677.
14. Feunou P.F., et al. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 2010, 28:7047-7053.
15. Mooi F.R., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 2009, 15:1206-1213.